WALTHAM, Massachusetts | April 9, 2026
Swedish Orphan Biovitrum (Sobi) has announced that Health Canada has approved EMPAVELI® (pegcetacoplan), marking a major regulatory milestone for the treatment of C3 glomerulopathy (C3G) and primary IC-MPGN, two rare and progressive kidney diseases. This approval makes EMPAVELI® the first targeted therapy available in Canada for these conditions in patients aged 12 years and older, offering a significant advancement in addressing diseases with historically limited treatment options. Backed by strong Phase 3 clinical evidence, this decision highlights the growing role of complement pathway inhibition in rare disease management and reinforces the importance of regulatory-driven innovation in biopharmaceutical development.
Phase 3 VALIANT Study Demonstrates Strong Clinical Outcomes
The approval is supported by data from the Phase 3 VALIANT study, a randomized, placebo-controlled trial evaluating the efficacy and safety of pegcetacoplan in both pediatric and adult patients. The study demonstrated significant clinical benefits across key endpoints, including a 68% reduction in proteinuria, stabilization of kidney function, and clearance of C3 deposits, which are central to disease progression.
These results, published in a leading medical journal, confirm the therapy’s ability to address the underlying disease mechanism rather than just symptoms, positioning EMPAVELI® as a disease-modifying treatment. The study also stands out as the largest clinical trial conducted in this rare disease population, further strengthening the evidence base for regulatory approval.
Targeted Complement Inhibition Addresses Unmet Medical Need
Advertisement
EMPAVELI® is a targeted C3 and C3b complement inhibitor, designed to regulate the overactivation of the complement cascade, a key driver of inflammation and kidney damage in C3G and IC-MPGN. These rare diseases affect a relatively small population but carry a high risk of progression to kidney failure, with more than 50% of patients developing end-stage renal disease within 5 to 10 years.
By targeting the root cause of complement dysregulation, EMPAVELI® offers a mechanism-based therapeutic approach that can potentially delay or prevent disease progression, reducing the need for dialysis or kidney transplantation. The approval underscores the importance of precision-targeted therapies in rare diseases, where treatment options are often limited and outcomes are poor.
Global Expansion and Regulatory Impact in Rare Diseases
The Health Canada approval further expands the global regulatory footprint of EMPAVELI®, which is already approved in multiple regions, including the United States and European Union for related indications. The collaboration between Sobi and Apellis Pharmaceuticals continues to drive the global development and commercialization of pegcetacoplan, demonstrating the importance of strategic partnerships in accelerating access to innovative therapies.
From a cGxP perspective, the approval reflects strict adherence to Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) standards, ensuring the safety, efficacy, and quality of the therapy. This milestone also highlights the increasing role of regulatory agencies in enabling access to breakthrough treatments for rare and life-threatening conditions, reinforcing the importance of compliance and evidence-based submissions in modern drug development.
The approval of EMPAVELI® by Health Canada represents a significant step forward in the treatment of rare kidney diseases, combining robust clinical evidence, innovative mechanism of action, and strong regulatory validation to deliver a much-needed therapeutic option for patients. By addressing the underlying complement-mediated disease process, EMPAVELI® sets a new standard in precision nephrology and rare disease management. This milestone demonstrates how biopharmaceutical innovation, clinical research excellence, and regulatory compliance can come together to improve patient outcomes and expand access to life-changing therapies globally.
Source: Sobi™ press release
